A pilot multi-centre randomised controlled trial of sequential treatme
A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Mitoxantrone
- Glatiramer acetate
Unknown
Compared with
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
Primary Endpoints: Multiple Sclerosis Impact Scale (MSIS)
Quality of life (reported by participants)
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: Definite MS as determined by the McDonald criteria (Ann Neurol, July 2001) with relapsing remitting disease course, clinical status should be stable or improving for 1 month prior to screening. Exclusion: a)Patients ever treated with GA, Mitoxantrone or Interferons.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Does sequential treatment with Mitoxantrone and Glatiramer Acetate (Copaxone) vs. Interferon Beta in early active relapsing remitting Multiple Sclerosis lead to better patient outcomes (in terms of the reduced relapses, reduced disability and improved quality of life)?
Loading reviews and guidelines…
Related trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- No Evidence Of Disease Activity After Autologous Haematopoietic Stem C
Phase 2 · Moved to EU CTIS registry
- A NIS Evaluating Various Injectable and Oral Treatments in Patients Wi
Recruiting
Still running
- Discontinuation of first-line disease modifying treatment (DMT) in lon
Phase 4 · Stopped early
Stopped
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
- A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple
Phase 4 · Stopped early
Stopped: safety
History
Started
Jun 2005